 Connection
Kyle Rove to Prostatic Neoplasms
This is a "connection" page, showing publications Kyle Rove has written about Prostatic Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.992 |
|
|
|
-
Rove KO, Crawford ED, Perachino M, Morote J, Klotz L, Lange PH, Andriole GL, Matsumoto AM, Taneja SS, Eisenberger MA, Reis LO. Maximal testosterone suppression in prostate cancer--free vs total testosterone. Urology. 2014 Jun; 83(6):1217-22.
Score: 0.260
-
Rove KO, Crawford ED. Traditional androgen ablation approaches to advanced prostate cancer: new insights. Can J Urol. 2014 Apr; 21(2 Supp 1):14-21.
Score: 0.259
-
Rove KO, Crawford ED. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer. Curr Opin Urol. 2013 May; 23(3):208-13.
Score: 0.243
-
Crawford ED, Rove KO. Advanced prostate cancer: therapeutic sequencing, outcomes, and cost implications. Am J Manag Care. 2012 12; 18(5 Spec No.):SP250-3.
Score: 0.237
-
Rove KO, Debruyne FM, Djavan B, Gomella LG, Koul HK, Lucia MS, Petrylak DP, Shore ND, Stone NN, Crawford ED. Role of testosterone in managing advanced prostate cancer. Urology. 2012 Oct; 80(4):754-62.
Score: 0.230
-
Rove KO, Crawford ED. Editorial comment. J Urol. 2012 Jun; 187(6):2049; discussion 2050.
Score: 0.226
-
Rove KO, Crawford ED. Evolution of treatment options for patients with CRPC and bone metastases: bone-targeted agents that go beyond palliation of symptoms to improve overall survival. Oncology (Williston Park). 2011 Dec; 25(14):1362-70, 1375-81, 1387.
Score: 0.221
-
Rove KO, Crawford ED. Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts. World J Urol. 2012 Apr; 30(2):137-42.
Score: 0.220
-
Rove KO, Crawford ED. Dutasteride: novel milestones in prostate cancer chemoprevention. Drugs Today (Barc). 2011 Feb; 47(2):135-44.
Score: 0.208
-
Rove KO, Flaig TW. A renaissance in the medical treatment of advanced prostate cancer. Oncology (Williston Park). 2010 Dec; 24(14):1308-13, 1318.
Score: 0.206
-
Crawford ED, Rove KO. Incomplete testosterone suppression in prostate cancer. N Engl J Med. 2010 Nov 11; 363(20):1976.
Score: 0.205
-
Rove KO, Sullivan KF, Crawford ED. High-intensity focused ultrasound: ready for primetime. Urol Clin North Am. 2010 Feb; 37(1):27-35, Table of Contents.
Score: 0.194
-
Crawford ED, Rove KO, Barqawi AB, Maroni PD, Werahera PN, Baer CA, Koul HK, Rove CA, Lucia MS, La Rosa FG. Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate. 2013 May; 73(7):778-87.
Score: 0.059
-
Crawford ED, Rove KO, Trabulsi EJ, Qian J, Drewnowska KP, Kaminetsky JC, Huisman TK, Bilowus ML, Freedman SJ, Glover WL, Bostwick DG. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol. 2012 Nov; 188(5):1726-31.
Score: 0.058
-
Oberley-Deegan RE, Steffan JJ, Rove KO, Pate KM, Weaver MW, Spasojevic I, Frederick B, Raben D, Meacham RB, Crapo JD, Koul HK. The antioxidant, MnTE-2-PyP, prevents side-effects incurred by prostate cancer irradiation. PLoS One. 2012; 7(9):e44178.
Score: 0.058
-
Crawford ED, Moul JW, Rove KO, Pettaway CA, Lamerato LE, Hughes A. Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone. BJU Int. 2011 Dec; 108(11):1743-9.
Score: 0.054
-
Barqawi AB, Rove KO, Gholizadeh S, O'Donnell CI, Koul H, Crawford ED. The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer. J Urol. 2011 Jul; 186(1):80-5.
Score: 0.053
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|